Interleukin 2 (IL 2), also known as T cell growth factor, is a lymphokine produced by amplifier T lymphocytes. The specific stimulation of immune T cells with antigen """"""""activates"""""""" T cells to express IL 2 receptors. IL 2 binds avidly to its receptor and induces T cell replication. In vitro, IL 2 induces the proliferation of """"""""activated"""""""" T cells capable of mediating a variety of differentiated effector functions. Similarly, we have recently shown that the administration of purified IL 2 in vivo can induce the growth of antigen-activated T cells, and thereby augment specific T cell function. Thus, by virtue of its potent action on lymphoid cells bearing IL 2 receptors, IL 2 may have significant therapeutic potential as a pharmacologic agent to augment specific T cell immunity in vivo.
The specific aims of the laboratory project are: to determine the pharmacologic potential of exogenous IL 2 by defining the influence of dose, route, and timing in inducing the growth and augmenting the function of specifically immune donor T cells in vivo; and to determine the effect of the IL 2 regimens developed on immune responses in both normal and immunodeficient mice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA001030-02
Application #
3079505
Study Section
(SRC)
Project Start
1985-07-01
Project End
1988-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Thompson, J A; Lee, D J; Lindgren, C G et al. (1989) Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 49:235-40
Thompson, J A; Lee, D J; Lindgren, C G et al. (1988) Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 6:669-78
Thompson, J A; Lee, D J; Cox, W W et al. (1987) Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 47:4202-7
Thompson, J A; Rubin, E; Fefer, A (1987) The treatment of hairy cell leukemia with alpha 2b-interferon: experience with 27 patients treated more than one year. Leukemia 1:328-30
Thompson, J A; Shields, A F; Porter, B A et al. (1987) Magnetic resonance imaging of bone marrow in hairy cell leukemia: correlation with clinical response to alpha-interferon. Leukemia 1:315-6
Thompson, J A; Cox, W W; Lindgren, C G et al. (1987) Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother 25:47-53
Thompson, J A; Fefer, A (1987) The treatment of hairy cell leukemia with recombinant alfa interferon: a multi-institutional study. Invest New Drugs 5 Suppl:S5-8
Thompson, J A; Peace, D J; Klarnet, J P et al. (1986) Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol 137:3675-80